Supernus Pharmaceuticals (SUPN) EBITDA Margin (2011 - 2025)
Supernus Pharmaceuticals' (SUPN) quarterly EBITDA Margin came in at 1.86% in Q4 2025, down 1415.0% year-on-year from 0.14% in Q4 2024, and up 94.06% on a QoQ basis from 31.35% in Q3 2025.
Supernus Pharmaceuticals (SUPN) EBITDA Margin (2011 - 2025) Analysis & Trends
Supernus Pharmaceuticals (SUPN) has 15 years of EBITDA Margin data on file, last reported at 1.86% in Q4 2025.
- On a quarterly basis, EBITDA Margin fell 1415.0% year-over-year to 1.86% in Q4 2025; TTM through Dec 2025 was 8.66%, a 2100.0% decrease from a year earlier, with the FY2025 full-year figure at 8.66%, down 2100.0% from the prior year.
- EBITDA Margin for Q4 2025 stood at 1.86%, up from 31.35% in the prior quarter.
- Over the last five years, EBITDA Margin for SUPN reached as high as 24.14% in Q2 2021 and fell as low as 31.35% in Q3 2025.
- Historically, EBITDA Margin has averaged 4.84% across 5 years, with a median of 4.56% in 2021.
- Across the five-year window, EBITDA Margin jumped 2638 bps in 2024 and tumbled 5460 bps in 2025, its largest moves.
- Year by year, EBITDA Margin stood at 3.83% in 2021, then jumped by 435 bps to 20.52% in 2022, then sank by 103 bps to 0.61% in 2023, then jumped by 2128 bps to 12.29% in 2024, then slumped by 115 bps to 1.86% in 2025.
- Per Business Quant data, the three most recent EBITDA Margin figures were 1.86% in Q4 2025, 31.35% in Q3 2025, and 7.34% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 16.37% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 36.83% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -38.02% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 41.69% |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -2.27% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.74% |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 21.23% |
| 10 | Supernus Pharmaceuticals | 2.72 Bn | 2.34 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -1.86% |
| Sep 30, 2025 | -31.35% |
| Jun 30, 2025 | 7.34% |
| Mar 31, 2025 | -6.85% |
| Dec 31, 2024 | 12.29% |
| Sep 30, 2024 | 23.25% |
| Jun 30, 2024 | 13.41% |
| Mar 31, 2024 | -2.20% |
| Dec 31, 2023 | -0.61% |
| Sep 30, 2023 | 5.29% |
| Jun 30, 2023 | -12.97% |
| Mar 31, 2023 | 3.37% |
| Dec 31, 2022 | 20.52% |
| Sep 30, 2022 | -0.86% |
| Jun 30, 2022 | 6.67% |
| Mar 31, 2022 | 1.29% |
| Dec 31, 2021 | 3.83% |
| Sep 30, 2021 | 21.96% |
| Jun 30, 2021 | 24.14% |
| Mar 31, 2021 | 10.09% |